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Key Concepts • Everyone is exposed to uranium in food, air, and water as part of 
the natural environment. Most exposures do not warrant 
monitoring or treatment. 
• Populations most heavily exposed to uranium are those employed 
in mining and milling operations, or in uranium enrichment and 
processing activities. 
• Natural and depleted uranium are primarily chemical toxicants, 
with radiation playing a minor role or no role at all. 
• Outcomes that may occur with uranium overexposure, based on 
both observed human effects and animal studies, include non-
malignant respiratory disease (fibrosis, emphysema) and 
nephrotoxicity. 
• Nephrotoxicity should reverse as overexposure ceases. 
• Alpha radiation (such as that from uranium) is classified as a 
human carcinogen. However, human studies have not found 
elevated rates of cancer from uranium exposure, and high-dose 
animal studies have not found cancer following inhalation, oral, or 
dermal exposure to uranium. 
About This and 
Other Case 
Studies in 
Environmental 
Medicine 
This educational case study document is one in a series of self-
instructional modules designed to increase the primary care 
provider’s knowledge of hazardous substances in the environment 
and to promote the adoption of medical practices that aid in the 
evaluation and care of potentially exposed patients. The complete 
series of Case Studies in Environmental Medicine is located on the 
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 ATSDR Web site at www.atsdr.cdc.gov/csem/. In addition, the 
downloadable PDF version of this educational series and other 
environmental medicine materials provides content in an electronic, 
printable format, especially for those who may lack adequate Internet 
service. 
How to Apply for 
and Receive 
Continuing 
Education Credit 
See Training and Continuing Education Online for more information 
about continuing medical education credits, continuing nursing 
education credits, and other continuing education units. 
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How to Use This Course 
Introduction The goal of the Case Studies in Environmental Medicine (CSEM) is to 
increase the primary care provider’s knowledge of hazardous substances 
in the environment and to help in evaluation and treating of potentially 
exposed patients. This CSEM focuses on uranium toxicity. 
Availability Two versions of the Uranium Toxicity CSEM are available. 
• The HTML version www.atsdr.cdc.gov/csem/uranium/ provides 
content through the Internet. 
• The downloadable PDF version provides content in an electronic, 
printable format, especially for those who may lack adequate Internet 
service. 
The HTML version offers interactive exercises and prescriptive feedback 
to the user. 
Instructions To make the most effective use of this course 
• Take the Initial Check to assess your current knowledge about 
uranium toxicity. 
• Read the title, learning objectives, text, and key points in each 
section. 
• Complete the progress check exercises at the end of each section and 
check your answers. 
• Complete and submit your assessment and posttest response online if 
you wish to obtain continuing education credit. Continuing education 
certificates can be printed immediately upon completion. 
Instructional 
Format 
This course is designed to help you learn efficiently. Topics are clearly 
labeled so that you can skip sections or quickly scan sections you are 
already familiar with. This labeling will also allow you to use this training 
material as a handy reference. To help you identify and absorb important 
content quickly, each section is structured as follows: 
 
Section Element Purpose 
Title Serves as a “focus question” that you should be able to answer after 
completing the section 
Learning 
Objectives 
Describes specific content addressed in each section and focuses your 
attention on important points 
Text Provides the information you need to answer the focus question(s) and 
achieve the learning objectives 
Key Points Highlights important issues and helps you review 
Progress Check Enables you to test yourself to determine whether you have mastered 
the learning objectives 
Answers Provide feedback to ensure you understand the content and can locate 
information in the text 
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Learning 
Objectives 
Upon completion of the Uranium Toxicity CSEM, you will be able to 
  
Content Area Objectives 
Overview • Describe uranium 
• Identify where uranium exists in the United States today 
Exposure 
Pathways 
• Identify the most common route of exposure to uranium  
Who Is at Risk • Identify the populations most heavily exposed to uranium 
• Describe who is at risk for uranium exposure 
Standards and 
Regulations  
• Describe the U.S. Occupational Safety and Health Administration’s 
(OSHA) permissible exposure limit (PEL) for uranium for workers 
• Describe the U.S. Environmental Protection Agency’s (EPA) 
maximum contaminant level (MCL) for uranium in drinking water 
Biological Fate • Identify where uranium is most likely to be retained in the body 
Pathogenic 
Changes 
• Identify the mechanism by which uranium induces pathogenic 
changes 
Physiologic 
Effects 
• Describe the medical conditions associated with uranium exposure 
Clinical 
Assessment 
• Identify the primary focus of the exposure and medical history 
• Describe the most typical biomarkers of effect 
Treatment and 
Management  
• Identify two primary strategies for managing uranium-exposed 
patients 
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Initial Check 
Instructions This Initial Check will help you to assess your current knowledge about 
uranium toxicity. To take the Initial Check, read the case below, and then 
answer the questions that follow. 
Case A 57-year-old man presents to his physician for a routine health 
maintenance visit. He believes that he is in good health. His review of 
systems reveals that he has a 3-year history of cough. Over the last 6 
months, the cough has been productive of small amounts of green or 
brownish material. He has a 40+ pack-year history of smoking. When 
asked about his work history, he indicates that he has been employed in 
a uranium milling plant for approximately 15 years and has been told 
that his occupational exposure to uranium may be harmful. There is no 
evidence of renal impairment. 
Initial Check 
Questions 
1. What information should be obtained during the examination? 
2. What additional tests should be conducted to assist with diagnosis 
and evaluation of exposure? 
3. Which diseases are linked to dusts or specifically uranium exposure? 
4. What risk factors may make the patient more likely to develop a 
uranium-related illness? 
Answers 1. What information should be obtained during the examination? 
The physician should take a full exposure and work history, 
including 
• job duties, 
• potential exposures at the work site, 
• frequency, source, and duration of exposure, 
• use of personal protective equipment at the work site, 
• other potential sources of exposure, including residential 
exposures (drinking water source, hobbies, etc.) and exposures 
to other hazardous materials in this and prior jobs, and 
• a history of tobacco use. 
More information for this answer can be found in the “Clinical 
Assessment” section. 
2. What additional tests should be conducted to assist with diagnosis 
and evaluation of exposure? 
• Renal function studies. 
• Pulmonary function studies. 
• Chest X-ray. 
More information for this answer can be found in the “Clinical 
Assessment” section. 
3. Which diseases are linked specifically to uranium exposure? 
Uranium exposure in the occupational setting has been associated 
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with relatively few medical problems. Renal disease is related to over-
exposure to uranium, but it s not specific to uranium. Pulmonary 
disease is related to dust exposure and is also not specific to 
uranium. These problems are also not related to exposure to 
radiation; such problems would not be expected unless the individual 
were handling highly enriched uranium. 
More information for this answer can be found in the “What Are the 
Physiologic Effects of Uranium Exposure?” section. 
4. What risk factors may make the patient more likely to develop a 
uranium-related illness? 
• Smoking status. 
• Prior renal disease. 
• Intensity, frequency, and duration of exposure. 
More information for this answer can be found in the “Clinical 
Assessment” section. 
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What Is Uranium? 
Learning 
Objectives 
Upon completion of this section, you will be able to 
•  describe uranium. 
Definition Uranium is a natural and commonly occurring radioactive element. 
Where Found 
 
Uranium is found in very small amounts in nature in the form of 
minerals, but it may be processed into a silver-colored metal. Rocks, soil, 
surface and underground water, air, and plants and animals all contain 
varying amounts of uranium. Typical concentrations in most materials 
are a few parts per million. 
Milling and 
Radioactive 
Wastes  
 
If the amount and concentration of uranium is great enough, it may be 
commercially mined. After the uranium-bearing ore is mined, it is 
converted into uranium dioxide or other chemical forms by a series of 
chemical processes known as milling. The residue remaining after the 
uranium has been extracted is called mill tailings. Mill tailings contain 
smaller concentrations of uranium, other naturally radioactive waste 
products such as radium and thorium, and process chemicals. The milled 
uranium is then processed to further purify it and prepare a portion for 
manufacture into nuclear reactor fuel or weapons material. The residual 
is used in industry and military applications. Specific information 
regarding locations and status of uranium mill sites and tailings can be 
found at the U.S. Nuclear Regulator Commission Fact Sheet on Uranium 
Mill Tailings [NRC 2006]. 
Three Types of 
Natural 
Uranium 
Natural uranium is a mixture of three types (or isotopes) of uranium, 
written as 234U, 235U, and 238U, or as U-234, U-235, and U-238, and read 
as uranium two thirty-four, etc. All three isotopes behave the same 
chemically, so any combination of the three would have the same 
chemical effect on a person’s health. 
But they are different radioactive materials with different radioactive 
properties. That is why we must look at the actual percentages of the 
three isotopes in a sample of uranium to determine how radioactive it is. 
Although natural and depleted uranium (discussed next) are primarily 
chemical hazards, the next few paragraphs describe the radiological 
nature of the toxicologically important uranium isotopes, because 
isotopes are addressed in some of the health effects studies. 
Radioactive elements are those that undergo spontaneous transformation 
(decay), in which energy is released (emitted) either in the form of 
particles, such as alpha or beta particles, or as electromagnetic radiation 
with energies sufficient to cause ionization, such as gamma or X-rays. 
This transformation or decay results in the formation of different 
elements, some of which may themselves be radioactive, in which case 
they will also decay. The process continues until a stable 
(nonradioactive) state is reached. 
When an atom of any of these uranium isotopes decays, it emits an 
alpha particle (the nucleus of a helium atom) and transforms into a 
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radioactive isotope of another element. The process continues through a 
series of radionuclides until reaching a stable, non-radioactive isotope of 
lead. The radionuclides in these transformation series (such as radium 
and radon) emit alpha, beta, and gamma radiations with energies and 
intensities that are unique to the individual radionuclide [ATSDR 2008b]. 
In addition, each isotope has a different radiological half-life or the 
amount of time it takes for one-half of the atoms of the radionuclide to 
transform. 234U has the shortest half-life and is, therefore, the most 
radioactive, followed by 235U and 238U. 
Processing The processing of uranium for industrial and governmental use changes 
the ratios of the different isotopes. If the fraction of 235U is increased, it 
is called enriched uranium. However, if the portion of 235U is decreased, it 
is called depleted uranium. Depleted uranium is less radioactive than 
natural uranium, and enriched uranium is more radioactive than natural 
uranium. When enriched uranium is 97.5% pure 235U, the same weight of 
enriched uranium is about 75 times more radioactive than natural 
uranium. This is because enrichment also increases the concentration of 
234U, which is the most radioactive of the three uranium isotopes. Natural 
uranium is typically about two times more radioactive than depleted 
uranium. Industrial processes produce other isotopes of uranium called 
232U, 233U and 236U. These are also much more radioactive than natural 
uranium.  
Natural 
Uranium 
Natural uranium is radioactive but poses more of a chemical hazard 
because its half-life is very long. When uranium gives off radiation, it 
transforms into another substance (such as radon). Unlike other kinds of 
radiation, the alpha radiation ordinarily given off by uranium cannot pass 
through solid objects, such as paper or human skin. Very small amounts 
of natural uranium are used to make some ceramic ornament glazes, 
light bulbs, photographic chemicals, and household products. Some 
fertilizers contain slightly higher amounts of natural uranium. 
Enriched 
Uranium 
Enriched uranium contains more of the fissionable 235U that is the energy 
source for reactors and weapons. Low-enriched uranium is used in 
civilian reactors. High-enriched uranium is used in Naval reactors and for 
weapons production. 
Depleted 
Uranium 
Depleted uranium (DU) is created as a byproduct of the uranium 
enrichment process and possesses about 60% of the radioactivity of 
natural uranium. Due to its high density, it can be used as radiation 
shielding material, as penetrators in cannon rounds, and as 
counterweights for aircraft control surfaces. 
Therefore, DU is used on helicopters and airplanes. It is also used by the 
armed forces as shielding to protect Army tanks and as parts of bullets 
and missiles to help them go through enemy armored vehicles. DU can 
contaminate wounds and become imbedded in soft tissue where direct 
contact with its high-energy alpha particles can be a source of systemic 
exposure over time. 
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Key Points • Uranium is a naturally occurring radioactive element. 
• Uranium emits alpha particles and gamma rays. 
• Uranium is enriched for nuclear fuel or weapons production. 
• DU is a highly dense byproduct of the uranium enrichment process. 
It is less radioactive than natural uranium, but is an important 
source of exposure to high-energy alpha radiation when embedded 
in soft tissues (i.e., shrapnel). 
• Uranium has both chemical and radiological properties. 
Progress 
Check 
1. Uranium is 
A. A radioactive element. 
B. A naturally occurring substance. 
C. Used in defense programs. 
D. All of the above. 
To review relevant content, see “Definition” and “Where Found” in 
this section. 
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Answers 1. The correct answer is D, all of the above. Uranium is a naturally 
occurring radioactive substance that is used in defense programs. 
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Where Is Uranium Found? 
Learning 
Objectives 
Upon completion of this section you will be able to 
• identify where uranium exists in the United States today. 
Introduction Uranium occurs naturally in the earth’s crust. In the United States, it is 
found most abundantly in the western states [EPA 2006a, b, c; Lide 
1994; USGS 2009b]. Enrichment of uranium for nuclear weapons began 
in the 1940s and for energy production in the 1950s. Gaseous diffusion 
was developed by the War Department (precursor to the Atomic Energy 
Commission and the Department of Energy (DOE)) as a way to enrich 
uranium. Uranium is currently used to fuel nuclear power plants, create 
medical isotopes, and for industrial and defense purposes. Detailed 
information on where uranium is found in the United States is available 
using the National Geologic Map Database [USGS 2008]. 
The Natural 
Environment 
Uranium is naturally present in the world’s environment. It is commonly 
found in 
• plants, 
• rock, 
• soil, 
• water, and 
• animals in small quantities. 
Uranium is present in the earth at approximately 3 parts per million 
(ppm). The most important uranium ores for commercial production 
include 
• autunite, 
• carnotite, 
• coffinite, 
• pitchblend, 
• tobernite, 
• tyuyamunite, and 
• uraninite, 
The majority of the uranium deposits in the United States are found in 
the western states of 
• Arizona, 
• Colorado, 
• Nebraska, 
• New Mexico, 
• Texas, 
• Utah, and 
• Wyoming. 
Uranium is radioactive and contributes to the natural background 
radiation levels in the environment [EPA 2009b]. For information on the 
location of uranium deposits in other areas of the United States, please 
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visit U.S. Geological Surveys website on Uranium Resources and 
Environmental Issues [USGS 2009a]. 
Uranium is redistributed on the Earth through various natural and 
anthropogenic processes. Volcanic eruptions, wind and water erosion, 
and other weathering processes can mobilize uranium into the 
atmosphere and redeposit it into other media.  
Industrial 
Processes 
Some industrial processes also contribute to the movement of uranium, 
including 
• extraction of phosphorus from phosphate ores to produce 
phosphate fertilizers, 
• uranium enrichment, 
• uranium mine tailings disposal, and 
• uranium mining and milling to produce uranium oxides. 
DOE and 
Civilian 
Reactor Sites 
Uranium processing (enrichment and reprocessing) occurred at a number 
of DOE sites beginning in 1943 and continues to the present day. DOE 
sites also store uranium and uranium wastes. Spent fuel rods are stored 
at civilian reactor sites. For information on the location of uranium sites 
in the United States, please visit the U.S. Geological Survey website 
Uranium Resources-Uranium Information System [USGS 2009b]. 
Key Points • Uranium occurs naturally in the Earth’s crust, water, air, and 
living organisms. 
• Uranium has been processed at U.S. government facilities since 
1943 and at commercial facilities since the 1950s. 
• Uranium enrichment and reprocessing still occurs in the United 
States. 
• DOE sites throughout the United States store uranium and 
uranium wastes. 
• Nuclear reactor fuel is uranium. The spent fuel rods stored at 
government and commercial sites retain a fraction of the original 
uranium. 
Progress 
Check 
2. Where is uranium found in the United States today? 
A. In residential and commercial products. 
B. Naturally occurring in the environment (including mine and mill 
tailings). 
C. At nuclear fuel production facilities. 
D. A and B 
E. All of the above. 
To review relevant content, see “Introduction” in this section. 
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Answers 2. The correct answer is E, all of the above. Uranium can be found in 
residential and commercial products, naturally occurring in the 
environment, at nuclear fuel and weapons production sites, and at 
civilian and government reactor sites. The majority of the uranium 
deposits in the United States are found in the western states, i.e., 
Arizona, Colorado, Nebraska, New Mexico, Texas, Utah, and 
Wyoming. 
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What Are the Routes of Exposure for Uranium? 
Learning 
Objectives 
Upon completion of this section, you will be able to 
•  identify the most common route of exposure to uranium  
Introduction Exposure to uranium in the natural environment occurs most commonly 
via oral exposures. Uranium enters the body by eating contaminated 
food or drinking water that contains uranium. 
Dermal exposures occur through skin contact with uranium powders or 
metals. Usually only those working with products or processes using 
uranium would be exposed in this way. Another possible route of 
exposure is from retained depleted uranium metal fragments (shrapnel) 
that embed in soft tissue. These fragments oxidize in situ and provide a 
source of ongoing systemic absorption. 
Inhalation of uranium powder can also occur and is the primary exposure 
route for workers. As discussed later in this section, inhalation may be an 
important route of exposure for individuals in “at risk” communities. 
Ingestion Ingestion is the most common pathway of exposure to naturally 
occurring uranium for the general public. Exposures can occur through 
• ingesting food or drinking water containing naturally occurring 
uranium and/or 
• ingesting food or drinking water contaminated through uranium 
mining or waste activities. 
Uranium is found in drinking water at an average concentration of 2.5 
micrograms/Liter (μg/L) throughout United States [Drury 1981; EPA 
2006a]. Uranium also adsorbs to plant roots and can be ingested during 
food intake. Overall, the daily estimated oral intake for both food and 
water is about 3.0 μg/day of natural uranium. In areas of the country 
where natural uranium concentrations are elevated, populations can be 
exposed to higher average doses of uranium. For information on the 
location of uranium deposits in the United States, please visit U.S. 
Geological Surveys website on Uranium Resources and Environmental 
Issues [USGS 2009a]. 
Inhalation Inhalation of uranium powder is the primary exposure route for workers. 
However, inhalation of uranium is a very minor source of exposure for 
the general population. Exposure scenarios include inhalation of 
contaminated air and dust from 
• communities where remediation activities are ongoing, 
• enrichment, or recycling, 
• mining and milling, 
• site remediation activities, 
• the combustion of coal (since it contains uranium), and 
• worker’s skin, hair, and clothing. 
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In areas where uranium enrichment processes occur, atmospheric 
concentrations of uranium have been measured at 200 times higher than 
normal background levels. Mining activities can increase air 
concentrations of uranium, exposing mine workers to elevated levels of 
uranium. Uranium enrichment processing also has potential to release 
additional uranium into the atmosphere. Both mining and processing of 
uranium have significantly decreased since the early 1990s, so that the 
highest exposures would have likely occurred prior to this. However, 
uranium mining for the purpose of either building or providing supplies 
for new nuclear power plants did increase some in the late 1990’s as 
sources of alternative energy were sought. Many of the Department of 
Energy mining and milling facilities have undergone or are undergoing 
remediation activities, which can also lead to increases in airborne 
uranium concentrations. This is currently the most likely exposure 
scenario for inhalation exposures 
Dermal Dermal contact with uranium is also a possible exposure pathway for 
naturally occurring uranium. Dermal exposure scenarios include 
• workers exposed to uranium powders or metals and 
• workers coming in contact with uranium wastes. 
It is not likely that community members would be exposed to elevated 
levels of uranium via direct skin contact, though children playing in 
contaminated areas may be at risk for this type of exposure. 
Key Points • The ingestion pathway, eating food and drinking water, is the most 
common route of exposure to natural uranium for the general public. 
• Inhalation of uranium also occurs and is the most common route of 
exposure for uranium workers. 
• Dermal contact is not usual outside the work setting. 
Progress 
Check 
3. The most common route of exposure for uranium workers is 
A. Inhalation. 
B. Ingestion. 
C. Dermal contact. 
D. A and B. 
To review relevant content, see “Introduction” and “Ingestion” in this 
section 
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Answers 3. The correct answer is A. The air pathway (inhalation of 
contaminated air and particles) is the most common route of 
occupational exposure to uranium and the route that most 
commonly leads to illness. Ingestion is the most common route of 
non-occupational exposure. 
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Who Is at Risk of Exposure to Uranium? 
Learning 
Objectives 
Upon completion of this section, you will be able to 
• identify the populations most heavily exposed to uranium and 
• describe who is at risk for uranium exposure. 
Introduction The occupations most heavily exposed to uranium are those employed in 
mining and milling operations, or in uranium enrichment and processing 
activities. 
Communities living near Department of Energy (DOE) facilities and 
mining sites and those living in areas where naturally occurring uranium 
levels are elevated are most at risk for significant environmental 
exposure. 
Past 
Occupational 
Exposures 
In the past, uranium exposure has been associated mainly with mining 
and milling of the raw material, with workers engaged in uranium 
enrichment, and processing (DOE sites). In the 1980s, the United States 
stopped recycling and reprocessing uranium for antiproliferation 
purposes (other than for military fuel), increasing the need for mining 
and material production. 
Past 
Paraoccupa-
tional 
Exposures 
In the past, industrial hygiene practices may not have been adequate to 
protect workers from bringing contamination home with them, resulting 
in possible exposures to family members. At DOE sites in the 1950s, in 
particular, workers often did not know the hazards they were working 
with due to the secrecy of the atomic weapon projects. While it is 
expected that workers became more aware of the industrial hazards after 
the end of World War II, industrial hygiene practices in general did not 
improve significantly until the mid-1970s. 
In addition, some releases from DOE facilities during the 1950s and 
1960s may have exposed nearby communities to elevated levels of 
radiation, including uranium. 
Current 
Occupational 
Exposures 
Very little mining or processing of uranium for the purpose of fuel or 
weapons development is currently underway. Occupational activities with 
potential for uranium exposure include workers involved in 
• using armor-piercing weapons, 
• decommissioning uranium-contaminated areas (e.g., handling 
wastes or debris suspected of containing uranium while 
decommissioning uranium contaminated areas), 
• processing nuclear fuel, 
• maintenance and/or repair activities at applicable U.S. 
government facilities, 
• mining or milling of uranium, silver, phosphorus, coal, etc., 
• producing phosphate fertilizer, 
• operating power plants, 
• repairing, storing, transporting and using uranium weapons, 
• working with gyroscope, helicopter rotor counterbalances, or 
control surfaces of aircraft containing uranium metal weights, or 
• using uranium-containing glazes as artists, hobbyists, and glass 
workers. 
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Direct 
Domestic 
Exposures 
As noted earlier, the most common non-occupational exposures are 
primarily a result of drinking water, eating food, and breathing air 
contaminated by naturally occurring uranium sources. 
Communities located near contaminated sites may be exposed through 
accidental releases during remediation activities. Essentially no uranium 
is released from nuclear power plants because of the fuel assembly 
design and the chemical and physical nature of the uranium oxide fuel 
[ATSDR 2008b]. 
Background 
Exposures 
Background exposures to uranium occur throughout the United States 
and the world because uranium is a naturally occurring element in the 
soil, water, and air. Average daily ingestion of uranium (both food and 
water) is estimated to be 3 micrograms (μg)/day in the United States. 
According to the Third National Report on Human Exposure to 
Environmental Chemicals, urine uranium levels were measured in a 
subsample of the National Health and Nutrition Examination Survey 
(NHANES) participants aged 6 years and older during 1999–2002. 
The 95th percentile of urinary uranium concentrations was 0.034 µg/gram 
(gram) creatinine in the 1999–2000 survey years and 0.040 µg/g 
creatinine in the 2001–2002 survey years for the U.S. population aged 6 
years and older [CDC 2009]. 
Key Points • Populations most heavily exposed to uranium are those employed in 
mining and milling operations, or in uranium enrichment and 
processing activities. 
• The most common nonoccupational exposures occur from exposure to 
naturally occurring uranium sources such as contaminated well water. 
• Communities located near mining sites or other potential sources of 
uranium contamination may also be at risk. 
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Progress 
Check 
4. In the past, occupations that entailed exposure to uranium included 
which of the following? 
A. Mining and milling of uranium. 
B. Repair and maintenance functions at uranium enrichment 
facilities. 
C. Processing nuclear fuel. 
D. All of the above. 
To review relevant content, see “Past Occupational Exposures” in this 
section. 
5. Of the following, who is LEAST likely to be at current risk of 
significant environmental uranium exposure? A person 
A. Living downwind of a uranium processing facility. 
B. Whose primary source of drinking water is a well contaminated by 
naturally occurring uranium. 
C. Living near a mine undergoing remediation activities. 
D. Living near a nuclear power plant. 
To review relevant content, see “Direct Domestic Exposures” in this 
section. 
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Answers 4. The correct answer is D, all of the above. In the past, various 
occupational exposures may have occurred during worker activities 
such as uranium mining and milling, repair and maintenance 
functions at facilities with exposure risk to uranium (such as 
uranium enrichment facilities), and nuclear fuel processing at 
uranium facilities. 
5. The correct answer is D. Of the choices listed, a person living near 
a nuclear power plant would be LEAST likely to be at current risk 
of significant environmental uranium exposure. Essentially no 
uranium is released from nuclear power plants because of the fuel 
assembly design and the chemical and physical nature of the 
uranium oxide fuel. 
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What Are the Standards and Regulations for Uranium Exposure? 
Learning 
Objectives 
Upon completion of this section you will be able to 
• describe the U.S. Occupational Safety and Health Administration’s 
(OSHA) permissible exposure limit (PEL) for uranium for workers and 
• describe the U.S. Environmental Protection Agency’s (EPA) maximum 
contaminant level (MCL) for uranium in drinking water. 
Introduction Uranium exposures are limited on the basis of both its chemical and 
radiological toxicities. In occupational settings, the Occupational Safety 
and Health Act regulates the limits of worker exposures based on the 
solubility of the uranium compound. The Department of Energy (DOE) 
has issued regulations applicable to its facilities that limit environmental 
discharges and worker exposure to uranium isotopes [DOE 2000, 2009]. 
The Nuclear Regulatory Commission (NRC) has also established 
standards and provisions for non-DOE environmental discharges and 
worker exposure to uranium isotopes [NRC 2009]. 
In addition, EPA has established standards for uranium concentrations in 
drinking water [EPA 2006a]. 
Workplace 
Standards 
OSHA established the permissible exposure level (PEL) for airborne 
insoluble uranium in the workplace as 0.25 milligram (mg)/cubic 
meter (m3) time weighted average (TWA). A TWA is the “average” 
exposure in any 8–hour work shift of a 40–hour work week. The PEL 
is the TWA concentration to which it is believed that nearly all 
workers may be repeatedly exposed, day after day, without adverse 
effect. Put another way, an employee's exposure to a given substance 
in any 8–hour work shift of a 40–hour work week, shall not exceed 
the 8–hour TWA limit given for that substance. This current limit was 
set based upon early animal study results [Voegtlin and Hodge 1953]. 
For more information on the OSHA PEL for insoluble uranium, please 
visit either OSHA’s TABLE Z-1 Limits for Air Contaminants–1910.1000 
TABLE Z-1 [OSHA 2006] or Safety and Health Topics Uranium (as U), 
Insoluble compounds [OSHA 2004]. 
Uranium is primarily an alpha-emitter. Workers exposed to various 
alpha-emitting uranium compounds protect themselves by wearing anti-
contamination clothing, eye protection, and respirators when 
appropriate. These protective barriers are designed to eliminate external 
alpha radiation exposure, for such barriers easily block alpha radiation. 
The OSHA PEL for airborne soluble uranium is 0.05 mg/m3. This is lower 
because soluble uranium compounds are absorbed to a greater extent by 
the body. For the same exposure, soluble uranium compounds are more 
likely to cause chemical effects than insoluble uranium. For more 
information on the OSHA PEL for soluble uranium , please visit either 
OSHA’s TABLE Z-1 Limits for Air Contaminants–1910.1000 TABLE Z-1 
[OSHA 2006] or Safety and Health Topics Uranium (as U), Insoluble 
compounds [OSHA 2004].  
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The NRC and DOE limit external radiation exposure to 5 REM per year. 
This is applicable to all sources combined, less background. The REM 
(Roentgen Equivalent Man) is the unit of dose actually absorbed taking 
biological effects into account. Both NRC and DOE have adopted internal 
exposure limits termed annual limits on intake (ALIs). The ALIs for 
inhalation or ingestion of uranium-238 are 10 microcurie/year for 
ingestion and 0.04-1 microcurie/year for inhalation of soluble and 
insoluble forms. For more information on the NRC and DOE ALIs, please 
visit NRC’s Appendix B to Part 20–Annual Limits on Intake (ALIs) and 
Derived Air Concentrations (DACs) of Radionuclides for Occupational 
Exposure; Effluent Concentrations; Concentrations for Release to 
Sewerage [NRC 2009]. 
Environmental 
Standards 
EPA has established a maximum contaminant level (MCL) for uranium of 
30 micrograms per liter (µg/L) in drinking water. The MCL is the 
maximum permissible level of a contaminant in water that is delivered to 
any user of a public water system. EPA finalized this MCL for uranium of 
30 µg/L in December 2000. Before this time, EPA did not have a limit 
specific to uranium in drinking water and instead regulated uranium 
content through gross alpha and gross beta limits. EPA's rule became 
effective in 2003. For more information on the EPA MCL, please visit 
either EPA’s Radionuclides in Drinking Water [EPA 2006a] or Radiation 
Protection–Uranium [EPA 2009b]. 
EPA established the Reportable Quantity Accidental Release standard, 
which requires that accidental uranium waste releases containing 0.1 
curies of radioactivity be cleaned up. 
In addition, EPA issued two standards for controlling uranium mill tailing 
hazards in 1983 and amended these in 1993. For more information on 
these standards, please see EPA’s Laws We Can Use Summary [EPA 
2009a]. 
They provide for the clean-up and disposal of mill tailings at abandoned 
sites and at licensed sites after operations cease. They require disposal 
and cleanup that will limit radium concentration in soil and radon 
emissions (decay products of uranium), protect groundwater, and 
prevent misuse. 
Key Points • OSHA’s PEL for insoluble uranium in the workplace is 0.25 mg/m3 (8–
hour TWA)). 
• OSHA’s PEL for soluble uranium in the workplace is 0.05 mg/m3 (8–
hour TWA). 
• EPA’s MCL for uranium in drinking water is 30 μg per liter of drinking 
water. 
• EPA regulates releases of uranium above 0.1 curie 
• EPA regulates the clean-up of closed uranium mill tailings sites. 
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Progress 
Check 
6. All of the following are true regarding the OSHA PEL of 0.05 mg/m3 
for airborne soluble uranium in the workplace EXCEPT 
A. It is an 8–hour TWA. 
B. It is lower than the insoluble uranium OSHA PEL because soluble 
uranium compounds are absorbed to a greater extent by the 
body. 
C. It is higher than the insoluble uranium OSHA PEL. 
D. For the same exposure, soluble uranium compounds are more 
likely to cause chemical effects than insoluble uranium. 
To review relevant content, see “Workplace Standards” in this 
section. 
7. EPA’s MCL of 30 micrograms per liter of uranium in drinking water 
refers to which of the following? 
A. The EPA marginal clean-up level for drinking water. 
B. The EPA maximum contaminant level allowed in drinking water. 
C. The EPA minimum contaminant level allowed in drinking water. 
D. None of the above. 
To review relevant content, see “Environmental Standards” in this 
section. 
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Answers 6. The best choice is C. OSHA’s PEL for soluble uranium in the 
workplace is lower not higher than the insoluble uranium OSHA 
PEL because soluble uranium compounds are absorbed to a greater 
extent by the body than insoluble compounds. 
7. The correct answer is B. EPA’s MCL for uranium is 30 μg per liter of 
drinking water. 
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What Is the Biologic Fate of Uranium in the Body? 
Learning 
Objectives 
Upon completion of this section, you will be able to 
• identify where uranium is most likely to be retained in the body. 
Introduction Health effects related to natural and depleted uranium exposures are 
related to the chemical properties of uranium, while effects from highly 
enriched uranium include a radiological component, since it is much more 
radioactive. Overall, absorption of uranium in the body is low, regardless 
of the route of exposure. 
Inhalation 
Exposure 
Inhaled uranium deposits in the various portions of the respiratory tract 
and the lungs based on particle size (i.e., larger particle size deposited 
higher in respiratory tract). Most of the deposited uranium clears rapidly 
via mucociliary transport to the throat. Once there, the uranium is 
cleared via sputum or swallowing and primarily fecal excretion. Soluble 
uranium dissolves and is absorbed into the circulatory system more 
rapidly than insoluble forms. A portion of the uranium can reside in the 
lungs for years. 
An analysis of uranium mill crushermen (workers in the dustiest section 
of the mill) found that 1–5% of inhaled uranium was absorbed 
systemically and excreted in urine and 95% was excreted in the feces 
[Fisher et al. 1983]. Other studies have suggested that only a small 
portion of inhaled uranium penetrates to the alveolar region, where it can 
remain for years [West and Scott 1969]. 
Ingestion 
Exposure 
From 0.5–5% of ingested uranium is absorbed into the blood in adults, 
with solubility of the compound influencing the portion that is absorbed. 
Fate of 
Ingested 
Uranium 
Animal studies indicate that absorbed uranium moves into the blood, 
where it is distributed first through soft tissues. Nearly 70% of the 
uranium absorbed in blood is filtered through the kidneys and cleared 
within 24 hours in urine. The remaining portion of uranium is distributed 
to other organs. 
After a few days, the majority of uranium exists in the kidneys and 
skeleton [Bhattacharyya et al. 1989]. A study of humans exposed to 
uranium showed the skeleton to be the primary long-term depot site for 
ingested uranium and all but the most insoluble forms of the element. 
Soft tissue sites of deposition include the liver and kidneys. For inhaled 
uranium, the pulmonary lymph nodes are the chief deposition site. 
Uranium deposition in bones first occurs on the surface, but the uranium 
eventually diffuses into the bone. Human exposure studies have shown 
that approximately 80–90% of bone deposition is cleared within 1–2 
years [ATSDR 2008b]. 
Overall, most ingested uranium is excreted in feces (95%) with the 
remainder eliminated in urine [Wrenn et al. 1985]. 
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Key Points • Most inhaled uranium is cleared through mucociliary transport, 
swallowed, and excreted in the feces. 
• A small portion of inhaled uranium is absorbed into the blood. 
• An even smaller fraction of ingested uranium is absorbed into the 
blood. 
• Ingested uranium is primarily excreted in feces. 
Progress 
Check 
8. Most inhaled uranium that reaches the lungs 
A. Becomes lodged and is retained in lung tissue. 
B. Is eliminated via mucociliary clearance. 
C. Is absorbed. 
D. Is exhaled. 
To review relevant content, see “Inhalation Exposure” in this 
section. 
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Answers 8. The correct answer is B. Most inhaled uranium that reaches the 
lungs is eliminated via mucociliary clearance. A very small fraction 
is absorbed into the blood stream, where it is distributed 
throughout the soft tissues and skeleton of the body. 
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How Does Uranium Induce Pathogenic Changes? 
Learning 
Objectives 
Upon completion of this section you will be able to 
• identify the mechanism by which uranium induces pathogenic 
changes. 
Introduction The body of evidence points to both natural and depleted uranium as 
being primarily chemical toxicants, with radiation playing a minor role or 
no role at all. Uranium has not been associated with human cancer, but 
if cancer were to occur, bone would be the most likely location. 
The primary target of uranium exposure is the kidney. However, most of 
the effects noted in humans have been due to high acute exposures. 
There is human evidence that kidney damage caused by occupational 
uranium overexposure can eventually heal after the excessive exposure 
ends [Hursh and Spoor 1973]. Uranium can cause acute renal failure in 
experimental models, and the pathologic changes are consistent with 
acute tubular necrosis. Recent studies in humans have not shown the 
same nephrotoxic effects as those in experimental animal studies 
[Kurttio et al. 2002, 2006]. 
Mechanisms A well-accepted theory for renal toxicity is the release of uranium from 
serum bicarbonate complex in the kidney that allows uranium to bind to 
available phosphate and protein. Irritation from overexposure produces 
most damage in the proximal convoluted tubule, followed by the 
glomerulus. Another theory includes uranium inhibition of mitochondrial 
ATPase activity and sodium transport mechanisms that can reduce the 
functionality and repair capacity of the epithelium [Keith et al. 2007]. 
The mechanism for lung damage is deep lung irritation that can degrade 
into fibrosis or emphysema. This can be associated with oxidative 
stress, altered gene expression, and inhibition of sodium-dependent 
phosphate and glucose transport systems [Keith et al. 2007]. 
Primary Sites 
Affected 
Uranium exposure primarily affects the kidneys (renal tubules), and 
inhalation exposure can also affect the lungs (alveolar changes). 
Carcinogenicity Alpha radiation, such as that from uranium, has been designated a 
human carcinogen. Therefore, since uranium is radioactive, exposure to 
uranium increases a person’s calculated risk of developing cancer. 
However, the Committee on the Biological Effects of Ionizing Radiation 
(BEIR IV) reported that eating food or drinking water that has 
background amounts of uranium will most likely not cause cancer or 
other health problems in most people. No human cancer of any type has 
ever been seen as a result of exposure to natural or depleted uranium. 
The chance of developing cancer is greater with exposure to enriched 
uranium, because it is more radioactive than natural uranium [ATSDR 
2008b]. 
The primary mechanism of toxicity would be direct damage to DNA from 
alpha particle interactions. If cancer were to occur, the most likely site 
would be bone (resulting in bone sarcomas). However, as previously 
mentioned, cancer has not been associated with uranium exposure. 
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The International Agency for Research on Cancer (IARC) and the U.S. 
National Toxicology Program (NTP) have no carcinogenicity ratings for 
uranium. The U.S. Environmental Protection Agency has withdrawn its 
carcinogenicity classification for uranium. The National Institute of 
Occupational Safety and Health (NIOSH) considers insoluble and soluble 
uranium compounds to be potential occupational carcinogens as defined 
by the U.S. Occupational Safety and Health Administration (OSHA) 
carcinogen policy [29 CFR 1990]. For more information, please see 
NIOSH’s Uranium (soluble compounds, as U) [NIOSH 1996]. 
The American Conference of Industrial Hygienists (ACGIH) considers 
insoluble and soluble uranium compounds Confirmed Human 
Carcinogens (A1). 
Carcinogenicity ratings are summarized on these OSHA websites: 
• Safety and Health Topics–Uranium (as U), Insoluble Compounds 
[OSHA 2004] and 
• Chemical Sampling Information–Uranium (as U), Soluble Compounds 
[OSHA 1999].  
Cancer among uranium miners has not been associated with exposure 
to uranium, but instead with exposure to radon progeny, diesel exhaust 
particles, arsenic, and other elements in the mine air which they 
breathe [ATSDR 1999 (updated 2008)]. 
Key Points • The process believed to account for uranium’s pathogenicity is 
uranium ion effects in the kidneys. 
• Alpha radiation (such as that from uranium) is classified as a human 
carcinogen. However, human studies have not found elevated rates 
of cancer from uranium exposure, and high-dose animal studies 
have not found cancer following inhalation, oral, or dermal exposure 
to uranium. 
Progress 
Check 
9. Some of the primary mechanisms by which natural and depleted 
uranium are theorized to induce pathogenic changes in tissue include 
A. Hepatic enzyme inhibition. 
B. Inflammation of the alveolar epithelium. 
C. Reactive uranyl ions released in kidney tubules. 
D. Both B and C. 
E. All of the above. 
To review relevant content, see “Mechanisms” in this section. 
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Answers 9. The correct answer is D. Some of the primary mechanisms by 
which natural and depleted uranium are theorized to induce 
pathogenic changes in tissue include inflammation of the alveolar 
epithelium and the release of reactive uranyl ions in the kidney 
tubules. Uranium has not been reported to affect hepatic enzymes. 
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What Are the Physiologic Effects of Uranium Exposure? 
Learning 
Objectives 
Upon completion of this section, you will be able to 
• describe the medical conditions associated with uranium exposure. 
Introduction The majority of adverse health outcomes related to uranium exposure 
have been observed in uranium mine, mill, and fabrication workers. 
Outcomes that may occur with uranium exposure based on both 
observed human effects and animal studies include 
• non-malignant respiratory disease (fibrosis, emphysema) and 
• nephrotoxicity 
o elevated β2 microglobulin, BUN, Non-protein nitrogen (NPN), 
o glucosuria, 
o proteinuria, 
o tubule degeneration, lesions and 
o cell necrosis. 
Extremely high acute exposures have also been lethal due to renal failure 
(from oral or inhaled exposure) or pulmonary failure (from inhalation 
exposure). 
In addition, uranium overexposure by either inhalation or ingestion is 
associated with renal abnormalities, regardless of solubility. However, 
there is some question as to whether the same cytotoxic effects to the 
kidney from exposure to uranium in experimental settings occurs in 
humans [Kurttio et al. 2002, 2006]. 
Additional health effects involving the reproductive/developmental 
systems and indicating potential neurologic effects from uranium 
exposure have been reported at higher doses in the literature and more 
studies have been indicated for some of them [ATSDR 1999].  
Nephrotoxicity 
in 
Experimental 
vs. Non-
Experimental 
Settings 
Recent studies have raised questions concerning the cytotoxic effects on 
the kidney from exposure to uranium in experimental animal settings vs. 
in humans. In one study of people drinking well water with high natural 
uranium concentrations, the median urinary concentration was 0.078 
microgram/Liter (µg/L) (ranging up to 5.65 µg/L). Here, a subtle effect of 
uranium on calcium and phosphate fractional clearance was indicated 
(within the normal range of these measures), but without effect on other 
biochemical or traditional markers of renal function [Kurttio et al. 2002]. 
In another study, uranium was measured in 193 people who used 
drinking water from drilled wells for an average of 16 years. Possible 
toxic effects of uranium on kidney cells and renal function were 
evaluated by measuring 
• urinary N-acetyl-gamma-D-glucosaminidase, 
• alkaline phosphatase, 
• lactate dehydrogenase, 
• gamma-glutamyltransferase and glutathione-S-transferase, 
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• serum cystatin C, 
• urinary and serum calcium phosphate, 
• glucose, and 
• creatinine. 
The study concluded that continuous uranium intake from drinking water, 
even at relatively high exposures, was not found to have cytotoxic effects 
on kidneys in humans [Kurttio et al. 2006]. 
Health Effect 
Differences 
between 
Children and 
Adults 
It is not known whether exposure to uranium affects children differently. 
No cases have been reported where exposure to uranium is known to 
have caused health effects in children. Very young animals absorb more 
uranium than adults do when fed uranium, but we do not know if this 
happens in children. 
It is also not known whether exposure to naturally occurring uranium can 
affect the developing human fetus. In laboratory animals, extremely high 
doses of uranium in drinking water resulted in birth defects and an 
increase in fetal deaths. We do not think that uranium can cause these 
problems in pregnant women who are exposed to background levels of 
uranium in food, water, and air. 
There is not a significant amount of information to suggest that children 
are affected differently than adults when exposed to uranium. 
Key Points • The majority of adverse health outcomes related to uranium exposure 
have been observed in uranium mine, mill, and fabrication workers. 
• Outcomes that may occur with uranium exposure based on both 
observed human effects and animal studies include non-malignant 
respiratory disease (fibrosis, emphysema) and nephrotoxicity. 
• Abnormalities consistent with nephrotoxicity include elevated β2 
microglobulin, BUN, Non-protein nitrogen (NPN), glucosuria, 
proteinuria, tubule degeneration, lesions and cell necrosis. 
• Nephrotoxicity should reverse as overexposure ceases. 
Progress 
Check 
10. Uranium may cause which of the following nephrotoxic effects? 
A. Cell necrosis. 
B. Tubule degeneration. 
C. Elevated β2 microglobulin. 
D. All of the above. 
To review relevant content, see “Introduction” in this section. 
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Answers 10. The correct answer is D, all of the above. Nephrotoxic effects of 
uranium exposure may include cell necrosis and tubule 
degeneration, leading to elevated levels of β2 microglobulin, BUN, 
and NPN, as well as proteinuria and glucosuria. As the dose 
increases, renal effects increase from none to elevated β2 
microglobulin, to tubular degeneration (potentially reversible), to 
cellular necrosis. 
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Clinical Assessment 
Learning 
Objectives 
Upon completion of this section, you will be able to 
• identify the primary focus of the exposure and medical history and 
• describe the most typical biomarkers of effect. 
Introduction In general, uranium at levels typically encountered in the community or 
in the workplace when normal protective measures are enforced has not 
been found to result in adverse health effects. Workers in the uranium 
milling industry have been shown to have early signs of renal toxicity, 
but these usually resolve after exposure is ended. Autopsies of highly 
exposed workers who died years after exposure ended found apparent 
complete repair of affected renal tissues. 
Uranium exposures in industrial settings often occur in the presence of 
other known toxicants such as 
• silica dust, 
• diesel exhaust particles, 
• radon, and 
• radium. 
Individuals who are exposed to uranium in an occupational setting may 
need to be assessed for these types of concurrent exposures. A typical 
patient evaluation should include 
• an exposure history, 
• a medical history, 
• a physical exam, and 
• an assessment of biomarkers of exposure and effect. 
Exposure 
History 
A detailed exposure history is an important step in evaluating a patient 
who may be at risk for health outcomes related to uranium exposure. In 
general, uranium at levels typically encountered in the community or in 
the workplace when normal protective measures are enforced has not 
been found to result in short-term or long-term adverse health effects. 
However, other concurrent exposures may be significant and could result 
in more serious health outcomes requiring further evaluation and 
treatment. Uranium exposure can result in reversible lung or kidney 
damage. 
A work history, including past occupations in which the patient may have 
been exposed directly or indirectly, is relevant in evaluating their 
exposures. Additionally, exposure histories should be evaluated in 
communities where naturally occurring uranium is elevated in air and 
water or where milling operations occur. Contact the local or state health 
department for assistance with finding information on uranium levels in 
air and water, especially levels in local aquifers likely to be tapped by 
private wells. 
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ATSDR’s case study Taking an Exposure History provides more 
information on taking an exposure history [ATSDR 2008a]. 
Medical 
History 
Knowing the complete medical history of a patient who has been exposed 
to uranium can help in making an accurate diagnosis. It is especially 
important to ask about renal function, since the kidney is the target 
organ for inhaled, ingested, and dermally absorbed uranium. 
In the case study, the findings are very nonspecific because uranium has 
no specific biomarkers of effect. The health care provider may wish to 
consider the possibility of bronchial irritation or pulmonary fibrosis 
associated with respective current and past inhalation overexposure to 
uranium. 
Physical Exam The primary toxic effect of uranium exposure is nephrotoxicity. There are 
very few physical findings associated with renal disease unless it is very 
severe. However, it is important to check patients for hypertension and 
edema. 
Biomarkers of 
Exposure and 
Effect 
Finding a measurable amount of uranium in urine does not mean that the 
level of uranium causes an adverse health effect. According to the Third 
National Report on Human Exposure to Environmental Chemicals, urine 
uranium levels were measured in a subsample of the National Health and 
Nutrition Examination Survey (NHANES). Participants in this survey were 
aged 6 years and older during 1999–2002. Participants were selected 
within the specified age range to be a representative sample of the U.S. 
population. 
The analytical method measured only levels of the U-238 isotope (99% 
naturally occurring) and not levels of the U-235 isotope (U-235 is higher 
in enriched uranium used as nuclear fuel). The 95th percentile of urinary 
uranium concentrations was .034 micrograms/gram (µg/g) creatinine in 
the 1999–2000 survey years and .040 µg/g creatinine in the 2001–2002 
survey years for the U.S. population aged 6 years and older [CDC 2009]. 
These urinary uranium levels provide physicians with a reference range 
so that they can determine whether people have been exposed to higher 
levels of uranium than are found in the general population. Whether 
uranium at these levels is cause for health concern is unknown. More 
research is needed. Urinary uranium analyses are not routinely available 
at typical hospital laboratories. 
A study looking at 105 people exposed to well water in South Carolina 
containing natural uranium in the range of 1.8 to 7770 µg/Liter (L) 
(median 157 µg/L) showed urinary levels of uranium as high as 9.55 
µg/L (median 0.162 µg/L) [Orloff et al. 2004]. 
The best way to evaluate acute uranium exposure and possible effects is 
through urine tests for uranium concentration (exposure) and markers of 
renal effects. Indicators of renal toxicity include urinary catalase, 
proteinuria, aminoaciduria, and clearance of β2-microglobulin relative to 
creatinine. 
The majority of uranium is cleared quickly from the body; therefore, high 
uranium concentrations in the urine (>100 μg/L) reflect current or recent 
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exposures, while low concentrations (<40 μg/L) are most likely a result 
of past exposures or typical background exposure. 
It is important to re-emphasize that elevated urine uranium 
concentrations indicate exposure, but they do not necessarily indicate 
adverse effects. In addition, biomarkers of effect (nephrotoxicity) are not 
unique to uranium exposure and should be considered in the whole of a 
patient’s exposure and medical history. 
No other laboratory tests are likely to be useful. 
Differential 
Diagnosis 
There are multiple causes of renal dysfunction; therefore, it is important 
to include a work history or an exposure history. If there is none, 
document the possibility of environmental exposure for communities with 
elevated levels of uranium in soil and water, as well as evaluate 
biomarkers of exposure and effect. In addition, there is no evidence for 
an effect of uranium as a carcinogen; other alpha-emitters are known to 
have greater effects and should be considered in evaluating cancer 
outcomes (e.g., radon exposure in uranium miners, especially in those 
who also smoke). 
Key Points • The exposure history focuses on occupational exposure or community 
exposure where uranium is elevated in soil or water. 
• The medical history focuses on renal function. 
• The most typical finding is elevated β2-microglobulin, proteinuria, and 
glucosuria. 
• Health effects from uranium are not easily differentiated from other 
causes without a clear history of exposure. 
Progress 
Check 
11. The most typical biomarkers of effect for a patient with uranium 
nephrotoxicity is 
A. Increased β2-microglobulin on urinalysis. 
B. Aminoaciduria. 
C. Proteinuria. 
D. All of the above. 
To review relevant content, see “Biomarkers of Exposure and Effect” 
in this section. 
12. Why is it important to know a patient’s exposure history? 
A. The biomarkers of effect are not unique to uranium exposure. 
B. Other concurrent exposures may be more toxic and more 
important to future patient care. 
C. It is important to determine if exposures are ongoing or occurred 
in the past. 
D. All of the above. 
To review relevant content, see “Exposure History” in this section. 
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Answers 11. The correct answer is D, all of the above. All of these biomarkers 
(β2-microglobulin, aminoaciduria, and proteinuria) for renal tubule 
toxicity are indicative of uranium overexposures. 
12. The correct answer is D, all of the above. The biomarkers of effect 
are not unique to uranium exposure, so an exposure history is very 
important in determining if uranium is indeed a cause of the health 
effects. It is also important to consider other concurrent exposures 
that may be more toxic and significant to the patient’s health. The 
exposure history is essential to determine if exposures are 
continuing and how the patient should proceed to minimize 
possible future health effects. 
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How Should Patients Exposed to Uranium Be Treated and Managed? 
Learning 
Objectives 
Upon completion of this section, you will be able to 
• identify two primary strategies for managing uranium-exposed 
patients. 
Introduction All patients are exposed to uranium in food, air, and water as part of 
their natural environment. Most exposures to naturally occurring 
uranium do not warrant monitoring or treatment. 
If 
Overexposure 
Is Suspected 
or Known 
The following steps are relevant if a recent uranium overexposure poses 
a potential health threat. 
• Remove the patient from the workplace or community source of 
overexposure, since renal damage normally reverses after 
overexposure ends. 
• Externally decontaminate patients to reduce further overexposure if 
they have residue from the exposure on them. 
If overexposure is apparent, you can contact the Radiation Emergency 
Assistance Center/Training Site (REAC/TS) for medical guidance 
[REACTS 2008]. 
REAC/TS: 
• is available 24 hours a day, 7 day a week to deploy and provide 
emergency medical services at incidents involving radiation anywhere 
in the world, 
• provides advice and consultation on radiation emergency medicine 
from its Oak Ridge, TN headquarters or at the scene of an incident, 
and 
• can be contacted for emergency assistance at 1-865-576-1005 (ask 
for REAC/TS) or the Internet at orise.orau.gov/reacts/ 
Care of patients who have been overexposed to uranium, whether or not 
they are symptomatic, should include the assessment of renal function to 
determine if the exposure may have caused renal damage. This may 
include measurement of uranium excreted in the urine (biomarker of 
exposure) as well as abnormalities in the clinical urinalyses (biomarkers 
of effect), as mentioned in the previous section. 
Monitoring Daily urine samples should be collected after large accidental 
overexposures [Diamond 1989; Howland 1949], and should continue for 
at least 2 weeks. The collection of 24–hour urine samples whenever 
possible is recommended. These samples can be used for both 
assessment of uranium excretion and for clinical urinalysis. 
For acute uranium nephrotoxicity, oral dose or infusions of sodium 
bicarbonate can be administered to maintain alkaline urine [Lincoln and 
Voelz 1990; MacNider 1916] with frequent monitoring of urine pH. 
Alkaline urine prevents dissociation of the uranium-bicarbonate complex 
that protects the renal tubular epithelium from exposure to the reactive 
uranyl ion. Forcing fluids to increase urinary output is recommended. 
Page 38 of 51 
Agency for Toxic Substances and Disease Registry Uranium Toxicity 
Case Studies in Environmental Medicine (CSEM) 
 
Treatment The use of chelation drugs for acute uranium overexposures is 
considered a controversial practice in the United States. No human cases 
of uranium overexposure have been reported as being treated with 
chelation in the Western world. Soviet research indicates that chelating 
agents can significantly reduce the risk of acute uranium injury to the 
kidneys [Ivannikov 1987]. However, chelation must begin within 4 hours 
of exposure to be effective, and it is most effective if given within a few 
minutes of the exposure. Some authors have advised against the use of 
chelation because precipitation of uranium in the kidney may cause 
additional damage. The avoidance of calcium DTPA for chelation is 
mentioned, as it can increase bone deposition. 
Instructions to 
Patients 
Patients whose exposures are a result of elevated water or food uranium 
concentrations from home or community sources should, as a matter of 
general principle, limit exposure by switching to bottled water or another 
water source known to contain uranium levels within U.S. Environmental 
Protection Agency limits. 
Key Points • Everyone is exposed to uranium in food, air, and water as part of 
his/her natural environment. Most exposures do not warrant 
monitoring or treatment. 
• Strategies for treatment and management of overexposed patients 
include removal from overexposure, decontamination, monitoring 
uranium biomarkers of exposure and biomarkers of effect 
(nephrotoxicity), administration of sodium bicarbonate to maintain an 
alkaline urine, and pushing fluids to increase urine output. 
• Nephrotoxicity should reverse as overexposure ceases. 
• REAC/TS is available to provide medical guidance in cases of 
overexposure. 
• Patient instructions include avoidance of overexposure by making 
behavioral changes in work and nonwork settings. 
Progress 
Check 
13. Standard treatment modalities in the United States for patients with 
acute uranium nephrotoxicity include which of the following? 
A. Administration of sodium bicarbonate. 
B. Urine monitoring for pH, uranium concentration, and biomarkers 
of effect. 
C. Chelation. 
D. Both A and B. 
E. All of the above. 
To review relevant content, see “Treatment” in this section. 
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Answers 13. The correct answer is D. Treatment modalities for patients with 
acute uranium nephrotoxicity do include administration of sodium 
bicarbonate to maintain an alkaline urine, and urine monitoring for 
pH, uranium concentration, and biomarkers of effect. The use of 
chelation drugs for acute uranium overexposures is considered a 
controversial practice in the United States and is not 
recommended. Nephrotoxicity should reverse on its own as 
overexposure ceases. 
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Sources of Additional Information 
Please refer to the following Web resources for more information on the 
adverse effects of uranium, the treatment of uranium-associated 
diseases, and management of persons exposed to uranium. 
Uranium 
Specific 
Information 
• Agency for Toxic Substances and Disease Registry (www.atsdr 
.cdc.gov/) 
o For chemical, emergency situations 
 CDC Emergency Response: 770-488-7100 and request 
the ATSDR Duty Officer 
o For chemical, non- emergency situations 
 CDC-INFO (www.bt.cdc.gov/coca/800cdcinfo.asp) 
 800-CDC-INFO (800-232-4636) TTY 888-232-6348 - 24 
Hours/Day 
 E-mail: cdcinfo@cdc.gov 
Please Note 
ATSDR cannot respond to questions about individual medical 
cases, provide second opinions or make specific 
recommendations regarding therapy. Those issues should be 
addressed directly with your health care provider. 
o Toxicological Profile for Uranium 
www.atsdr.cdc.gov/toxprofiles/tp150.html  
o ToxFAQs™ for Uranium www.atsdr.cdc.gov/tfacts150.html, or 
(Spanish) www.atsdr.cdc.gov/es/toxfaqs/es_tfacts150.html  
o Case Studies in Environmental Medicine – Radon Toxicity 
www.atsdr.cdc.gov/csem/radon/ 
• EPA’s Radiation Information on Uranium 
www.epa.gov/radiation/radionuclides/uranium.html 
• Radiation Emergency Assistance Center/Training Site (REAC/TS) 
orise.orau.gov/reacts/ 
o Provide 24/7 availability to deploy and provide emergency 
medical services at incidents involving radiation anywhere in the 
world. 
o Provide advice and consultation on radiation emergency medicine 
from its Oak Ridge, TN, headquarters or at the scene of an 
incident. 
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• American College of Occupational and Environmental Medicine 
(ACOEM) (www.acoem.org) 
Clinical 
Resources 
o ACOEM is the nation's largest medical society dedicated to 
promoting the health of workers through preventive medicine, 
clinical care, research, and education. 
o Its members are a dynamic group of physicians encompassing 
specialists in a variety of medical practices is united via the 
College to develop positions and policies on vital issues relevant 
to the practice of preventive medicine both within and outside of 
the workplace. 
• American College of Medical Toxicologists (ACMT) (www.acmt.net) 
o ACMT is a professional, nonprofit association of physicians with 
recognized expertise in medical toxicology. 
o The College is dedicated to advancing the science and practice of 
medical toxicology through a variety of activities. 
• Association of Occupational and Environmental Clinics www.aoec.org  
o The Association of Occupational and Environmental Clinics (AOEC) 
is a network of more than 60 clinics and more than 250 
individuals committed to improving the practice of occupational 
and environmental medicine through information sharing and 
collaborative research. 
• Pediatric Environmental Health Specialty Units (PEHSUs) 
www.pehsu.net 
o Each PEHSU is based at an academic center and is a collaboration 
between the pediatric clinic and the (AOEC) occupational and 
environmental clinic at each site. 
o The PEHSU's have been developed to provide education and 
consultation for health professionals, public health professionals 
and others about the topic of children's environmental health.  
o The PEHSU staff is available for consultation about potential 
pediatric environmental health concerns affecting both the child 
and the family. Health care professionals may contact their 
regional PEHSU site for clinical advice. 
• Poison Control Center 
o The American Association of Poison Control Centers may be 
contacted for questions about poisons and poisonings. The web 
site provides information about poison centers and poison 
prevention. AAPC does not provide information about treatment 
or diagnosis of poisoning or research information for student 
papers. 
o American Association of Poison Control Centers (1-800-222-1222 
or www.aapcc.org). 
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• Agency for Toxic Substances and Disease Registry 
(www.atsdr.cdc.gov) 
General 
Environmental 
Health 
Information o To view the complete library of CSEMs 
(www.atsdr.cdc.gov/csem/). 
o Taking an Exposure History CSEM 
(www.atsdr.cdc.gov/csem/exphistory/). 
• Environmental Protection Agency Integrated Risk Information System 
(IRIS) cfpub.epa.gov/ncea/iris/index.cfm  
o IRIS is a compilation of electronic reports on specific substances 
found in the environment and their potential to cause human 
health effects. 
o Initially developed for EPA staff in response to a growing demand 
for consistent information on substances for use in risk 
assessments, decision-making and regulatory activities. 
o The information in IRIS is intended for those without extensive 
training in toxicology, but with some knowledge of health 
sciences. 
• National Center for Environmental Health (NCEH) 
(www.cdc.gov/nceh/) 
o NCEH works to prevent illness, disability, and death from 
interactions between people and the environment. It is especially 
committed to safeguarding the health of populations that are 
particularly vulnerable to certain environmental hazards - 
children, the elderly, and people with disabilities. 
o NCEH seeks to achieve its mission through science, service, and 
leadership. 
• National Institute of Health (NIH) (www.nih.gov) 
o A part of the U.S. Department of Health and Human Services, NIH 
is the primary Federal agency for conducting and supporting 
medical research. 
• National Institute of Occupational Safety and Health (NIOSH) 
(www.cdc.gov/niosh/) 
o NIOSH is in the U.S. Department of Health and Human Services 
and is an agency established to help assure safe and healthful 
working conditions for working men and women by providing 
research, information, education, and training in the field of 
occupational safety and health. 
• National Library of Medicine's (NLM) Environmental Health and 
Toxicology sis.nlm.nih.gov/enviro.html 
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Assessment and Posttest Instructions 
Introduction ATSDR seeks feedback on this course so we can asses its usefulness 
and effectiveness. We ask you to complete the assessment 
questionnaire online for this purpose. In addition, if you complete the 
assessment and posttest online, you can receive continuing education 
credits as follows. 
 
Accrediting 
Organization 
Credits Offered 
Accreditation Council for 
Continuing Medical 
Education (ACCME) 
CME: The Centers for Disease Control and Prevention is 
accredited by the Accreditation Council for Continuing Medical 
Education (ACCME) to provide continuing medical education for 
physicians. The Centers for Disease Control and Prevention 
designates this educational activity for a maximum of 1.75 AMA 
PRA Category 1 Credit(s)™. Physicians should only claim 
credit commensurate with the extent of their participation in the 
activity. 
American Nurses 
Credentialing Center 
(ANCC), Commission on 
Accreditation 
CNE: The Centers for Disease Control and Prevention is 
accredited as a provider of Continuing Nursing Education by the 
American Nurses Credentialing Center's Commission on 
Accreditation. This activity provides 1.7 contact hours. 
National Commission for 
Health Education 
Credentialing, Inc. 
(NCHEC) 
CHES: The Centers for Disease Control and Prevention is a 
designated provider of continuing education contact hours 
(CECH) in health education by the National Commission for 
Health Education Credentialing, Inc. This program is a 
designated event for the Certified Health Education Specialist 
(CHES) to receive 2.0 Category I contact hours in health 
education, CDC provider number GA0082. 
International Association 
for Continuing Education 
and Training (IACET) 
CEU: The CDC has been approved as an Authorized Provider by 
the International Association for Continuing Education and 
Training (IACET), 1760 Old Meadow Road, Suite 500, McLean, 
VA 22102. The CDC is authorized by IACET to offer 0.2 IACET 
CEU's for this program. 
 
Disclaimer  CDC, our planners, and our presenters wish to disclose they have no 
financial interests or other relationships with the manufacturers of 
commercial products, suppliers of commercial services, or commercial 
supporters. Presentations will not include any discussion of the unlabeled 
use of a product or a product under investigational use. There was no 
commercial support received for this activity. 
Online 
Instructions 
To complete the assessment and posttest, go to www2.cdc.gov/atsdrce/ 
and follow the instructions on that page. 
You can immediately print your continuing education certificate from your 
personal transcript online. No fees are charged. 
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Posttest 1. Uranium is found naturally in 
A. Rocks. 
B. Soils. 
C. Animals. 
D. Water. 
E. All of the above. 
F. None of the above. 
2. Where can uranium be found in the United States today? 
A. Naturally occurring in the environment (including mine and mill tailings). 
B. At nuclear fuel production facilities. 
C. In residential and commercial products. 
D. All of the above. 
E. Both A and B only. 
3. Enriched uranium 
A. Contains more U-235 than natural uranium. 
B. Is less radioactive than natural uranium. 
C. Has diverse therapeutic uses. 
D. Is created when meteors strike the earth. 
4. Uranium is used 
A. In nuclear power plants. 
B. To counter balance helicopter blades. 
C. As armor for military vehicles. 
D. As a part of certain kinds of bullets. 
E. All of the above. 
F. None of the above. 
5. In the past, occupations that entailed exposure to uranium included which of 
the following? 
A. Uranium miners and millers. 
B. Repairmen and maintenance workers at uranium enrichment facilities. 
C. Nuclear fuel processors. 
D. All of the above. 
6. Of the following, who is LEAST likely to currently be at risk of significant 
environmental uranium exposure? A person 
A. Living downwind of a uranium processing facility. 
B. Whose primary source of drinking water is a well contaminated by 
naturally occurring uranium. 
C. Living near a mine undergoing remediation activities. 
D. Living near a nuclear power plant. 
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7. In general, exposure to uranium in the natural environment occurs primarily 
via 
A. Inhalation. 
B. Ingestion. 
C. Dermal contact. 
D. None of the above. 
8. Which of the following is FALSE regarding the OSHA PEL of 0.05 mg/m3 for 
airborne soluble uranium in the workplace? 
A. It is an 8–hour, time-weighted average. 
B. It is lower than the insoluble uranium OSHA PEL because soluble uranium 
compounds are absorbed to a greater extent by the body. 
C. It is higher than the insoluble uranium OSHA PEL. 
D. For the same exposure, soluble uranium compounds are more likely to 
cause chemical effects than insoluble uranium. 
9. EPA’s MCL of 30 micrograms per liter of uranium in drinking water refers to 
which of the following? 
A. The EPA marginal clean-up level for drinking water. 
B. The EPA maximum contaminant level allowed in drinking water. 
C. The EPA minimum contaminant level allowed in drinking water. 
D. None of the above. 
10. Most inhaled uranium that reaches the lungs 
A. Becomes lodged and is retained in lung tissue. 
B. Is eliminated via mucociliary clearance. 
C. Is absorbed. 
D. Is exhaled. 
11. The radioactivity from uranium is primarily 
A. Alpha particles. 
B. Beta particles. 
C. Gamma rays. 
D. Muons. 
E. All of the above. 
F. None of the above. 
12. Exposure to natural uranium increases a person’s risk of getting cancer 
A. True. 
B. False. 
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13. Exposure to uranium is associated with 
A. Heart disease. 
B. Emphysema. 
C. Rheumatologic disease. 
D. Renal disease. 
E. Neurodegenerative disease. 
F. All of the above. 
G. Only B and D. 
H. None of the above. 
14. The most typical biomarkers of effect for a patient with uranium 
nephrotoxicity is 
A. Increased β2-microglobulin on urinalysis. 
B. Aminoaciduria. 
C. Proteinuria. 
D. All of the above. 
15. Why is it important to know a patient’s exposure history? 
A. The biomarkers of effect are not unique to uranium exposure. 
B. Other concurrent exposures may be more toxic and more important to 
future patient care. 
C. It is important to determine if exposures are ongoing or occurred in the 
past. 
D. All of the above. 
16. Biomarkers of uranium exposure include 
A. The presence of uranium in feces. 
B. Pathognomonic changes in an EMG (electromyogram). 
C. The chemical or radiological detection of uranium in the urine. 
D. Both A and C. 
E. All of the above. 
F. None of the above. 
17. Standard treatment modalities in the United States for patients with acute 
uranium nephrotoxicity include which of the following? 
A. Administration of sodium bicarbonate. 
B. Urine monitoring for pH, uranium concentration and biomarkers of effect. 
C. Chelation. 
D. Both A and B. 
E. All of the above. 
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Relevant 
Content 
To review content relevant to the posttest questions 
  
Question Location of Relevant Content 
1 What Is Uranium? 
2 Where Is Uranium Found? 
3 What Is Uranium? 
4 What Is Uranium? 
5 Who Is at Risk of Exposure to Uranium? 
6 Who Is at Risk of Exposure to Uranium? 
7 What Are Routes of Exposure for Uranium? 
8 What Are Standards and Regulations for Uranium Exposure? 
9 What Are Standards and Regulations for Uranium Exposure? 
10 What Is the Biologic Fate of Uranium in the Body? 
11 How Does Uranium Induce Pathogenic Change? 
12 How Does Uranium Induce Pathogenic Change? 
13 What are the Physiologic Effects of Uranium Exposure? 
14 Clinical Assessment 
15 Clinical Assessment 
16 Clinical Assessment 
17 How Should Patients Exposed to Uranium Be Treated and Managed? 
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